The overall ratings of three Medical Devices stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
ZELTIQ Aesthetics Inc. (NASDAQ:ZLTQ) earns a F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). In Portfolio Grader’s specific subcategories of Equity and Cash Flow, ZLTQ also gets F’s. The stock price has dropped 13.2% over the past month, worse than the 5.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ZLTQ stock.
RTI Biologics‘ (NASDAQ:RTIX) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. RTI Biologics processes human and animal musculoskeletal tissues in producing allograft and xenograft implants. Wall Street appears to agree with the stock downgrade, with share prices dropping 8.3% over the past month. The trailing PE Ratio for the stock is 27.30. For a full analysis of RTIX stock, visit Portfolio Grader.
Staar Surgical (NASDAQ:STAA) earns a F this week, falling from last week’s grade of D. Staar Surgical develops, manufactures, and markets high margin visual implants that improve a patient’s quality of vision. The stock also gets an F in Earnings Growth. Share prices fell 34% over the past month. The stock has a trailing PE Ratio of 509.00. To get an in-depth look at STAA, get Portfolio Grader’s complete analysis of STAA stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.